Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07041281 · ClinicalTrials.gov registry record · Phase 2
Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories
A Phase 2 study of Preeclampsia and Gestational Hypertension, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 204
- Enrollment target
- 3
- Study locations
NCT07041281: Recruiting Phase 2 study of Preeclampsia and Gestational Hypertension, sponsored by Massachusetts General Hospital.
NCT07041281 is a Phase 2 study of Preeclampsia and Gestational Hypertension that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 204 participants, below the 1,122-participant average among 48 other Preeclampsia trials with a reported enrollment target (82% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07041281, a Phase 2 study of Preeclampsia and Gestational Hypertension, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 204 participants
- Enrollment target
- 3
- Study locations
Study Summary
The hypertensive disorders of pregnancy (preeclampsia and gestational hypertension) are associated with increased long-term maternal risk of developing cardiovascular disease. Recent evidence suggests that activation of the mineralocorticoid receptor promotes ongoing susceptibility to hypertension in women following hypertensive disorders of pregnancy. In addition, women with overweight/obesity are at increased risk for progression to chronic hypertension after experiencing hypertensive disorders of pregnancy. Among women with hypertensive disorders of pregnancy and pre-pregnancy overweight/obesity, the investigators will conduct a randomized trial to test the effect of pharmacologically blocking the mineralocorticoid receptor for three months after delivery on blood pressure and cardiac remodeling at nine months postpartum.
Primary Outcome
24-hour BP monitoring will be performed as part of end-of-study assessments using a validated ambulatory BP monitor.
Conditions Studied
Interventions
- DRUG spironolactone 25 mg orally once daily
- DRUG Placebo tablet to match spironolactone
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
Pennsylvania
- University of Pittsburgh Magee-Womens Hospital - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2025-10-16 |
| Est. Completion | 2029-03-02 |
| Phase | Phase 2 |
What NCT07041281 shows while recruiting
NCT07041281 is an interventional study that assigns participants to a tested intervention. The registered 204 participants enrollment target is mid-sized for trials with a published cap, below the 1,122-participant average among 48 other Preeclampsia trials with a reported enrollment target (82% lower).
The record links to 2 conditions, with Preeclampsia appearing as the primary indexed condition, and to 2 interventions - of which spironolactone 25 mg orally once daily is the first listed.
NCT07041281 reports a single indexed study location in Massachusetts, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07041281 about?
NCT07041281 is a clinical study titled "Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories". The hypertensive disorders of pregnancy (preeclampsia and gestational hypertension) are associated with increased long-term maternal risk of developing cardiovascular disease. Recent evidence suggests that activation of the mineralocorticoid receptor promotes ongoing susceptibility to hypertension i...
What is the current status of trial NCT07041281?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 204 participants. The study started on 2025-10-16. Estimated completion is 2029-03-02.
What conditions does trial NCT07041281 study?
This clinical trial studies the following conditions: Preeclampsia, Gestational Hypertension.
What interventions are being tested in trial NCT07041281?
The interventions under investigation include: spironolactone 25 mg orally once daily (DRUG), Placebo tablet to match spironolactone (DRUG).
Who is sponsoring clinical trial NCT07041281?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07041281 being conducted?
This trial has 3 study locations across Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Preeclampsia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07041281's enrollment target sits among peer trials
204 20th of 48 higher than 29 of 48 other Preeclampsia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Preeclampsia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders
RECRUITING · Phase 2
-
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
RECRUITING · NA
-
Daily Aspirin Treatment After Preeclampsia
RECRUITING · Early Phase 1
-
Optimizing Cardiovascular Preventive Care for Women Following Hypertensive Disorders of Pregnancy
RECRUITING · NA
-
Exosome Cargo From Preeclampsia Patients
RECRUITING
-
Prenatal Aspirin and Postpartum Vascular Function
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
- NCT04249830 · 204 participants · NA
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
- NCT04503395 · 204 participants · NA
ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES
- NCT04793776 · 204 participants · NA
Manage Emotions to Reduce Aggression (MERA)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI